Company

NextPoint Therapeutics, Inc.

NextPoint Therapeutics develops immunotherapies for cancer based on HHLA2 biology and clinical biomarkers.

About

NextPoint Therapeutics develops cancer immunotherapies that target HHLA2-driven immune evasion and use clinical biomarkers, including HHLA2 expression. Founded in 2020, the biotechnology company is based in Massachusetts, US. Leaps by Bayer and Sanofi Ventures co-led its USD 80 million Series B round in December 2022, with Catalio Capital Management, Invus, PagodaTree Partners, and Sixty Degree Capital participating.

1Funding rounds

8Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in